Epidermal growth factor receptor (EGFR) gene is frequently mutated and is a well-known genetic aberration in Non-small cell lung cancer (NSCLC), a leading cause of cancer mortality worldwide. Some EGFR activating mutations, among which L858R, L861Q, and exon 19 deletions are predictive of disease responsiveness to targeted therapy using tyrosine kinase inhibitors (TKls) like Osimertinib. On the contrary, the presence of EGFR T790M or C797S mutations is associated with tumor resistance to certain TKIs.

Download the full application note: